Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma ProjectDennis D. Weisenburger, Kerry J. Savage, Nancy L. Harris et al.|Blood|2011Cited by 431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s LymphomaStephen M. Ansell, David J. Straus, John Radford et al.|New England Journal of Medicine|2022Cited by 342
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen et al.|Journal of Clinical Oncology|2019Cited by 154
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009Yok‐Lam Kwong, Soon-Thye Lim, Benjamin O. Anderson et al.|The Lancet Oncology|2009Cited by 120
The Role of<sup>18</sup>F-FDG PET/CT for Initial Staging of Nasal Type Natural Killer/T-Cell Lymphoma: A Comparison with Conventional Staging MethodsSeung Hwan Moon, Joon Young Choi, Byung‐Tae Kim et al.|Journal of Nuclear Medicine|2013Cited by 73